A combination of targeted cancer drugs, also known as receptor tyrosine kinases, can outsmart tumor cells by preventing protein switches from inciting cell growth, U.S. researchers report. However, scientists said further studies are needed before the combination treatments can be recommended to cancer patients, given the drugs' possible toxicity risk and high cost.

Related Summaries